^
Association details:
| Biomarker: | KIT exon 8 mutation |
|---|---|
| Cancer: | Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II clinical trial for Dasatinib combined with chemotherapy in the treatment of pediatric acute myeloid leukemia (AML) companying C-KIT mutation: an addition of CALS III-AML protocol
Excerpt:
...Patients with CBF AML (RUNX1-RUNX1T1 or CBFB-MYH11) with a single KIT mutation (whether exon 8 or exon 17) are eligible to receive dasatinib combined with chemotherapy and are not candidates for HCT in first remission; 3. ...
Trial ID:
Source:
Title:
Dasatinib Plus Chemotherapy in Core Binding Factor Leukemia: A Case Study
Published date:
09/14/2020
Excerpt:
We report a case of a relapsing inv(16) CBF leukemia salvaged by adding a tyrosine kinase inhibitor (TKI) to the chemotherapeutic regimen….21-year-old patient with quadriplegia and inv16 with mutated KIT exon 8 gene diagnosed...Salvage therapy was initiated with decitabinevenetoclax-gentuzumab ozogamicin (GO)....Due to the persistence of the KIT mutation, the TKI dasatinib was added to decitabine-venetoclax-gentuzumab ozogamicin (GO).... After the TKI addition, she remained in CR.
Secondary therapy:
decitabine
